Lyell ImmunopharmaLYEL
About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Employees: 224
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
21% more call options, than puts
Call options by funds: $17K | Put options by funds: $14K
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
0.15% less ownership
Funds ownership: 52.45% [Q1] → 52.3% (-0.15%) [Q2]
6% less funds holding
Funds holding: 125 [Q1] → 118 (-7) [Q2]
23% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 44
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
35% less capital invested
Capital invested by funds: $298M [Q1] → $194M (-$104M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Mitchell Kapoor 50% 1-year accuracy 66 / 133 met price target | 15%downside $1 | Neutral Reiterated | 19 Aug 2024 |
